Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Countries in need will have access to Moderna COVID-19 vaccine tech

By Sean Whooley | March 8, 2022

ModernaModerna (Nasdaq:MRNA) announced four new initiatives within a global public health strategy for advancing mRNA vaccines.

Cambridge, Massachusetts-based Moderna plans to expand its global public health portfolio, accelerate research in an effort to advance additional vaccines, expand its patent pledge to never enforce COVID-19 patents in the Gavi COVAX AMC for 92 low- and middle-income countries and establish Kenya as the location for its mRNA manufacturing facility.

“Kenya was selected to be the site of our future manufacturing facility due to its existing strengths in the life sciences industry and international trade,” said a Moderna spokesperson. “In addition, the overall domestic regulatory environment positions Kenya as an efficient supply hub for the entire African continent.  These advantages will be further enhanced through cooperation between Kenya and the U.S. Government on workforce training and capacity building. Together, these attributes made Kenya a natural and attractive choice for Moderna’s new facility, as we work to bring up to 500 million vaccine doses to the African continent each year.”

According to a news release, Moderna intends to expand its global public health portfolio to 15 vaccine programs targeting priority pathogens that threaten global health, advancing those vaccines into clinical studies by 2025. The company plans to prioritize development efforts against pathogens identified as persistent global health threats, including HIV, tuberculosis (TB) and malaria, neglected tropical diseases and the priority pathogens of the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI).

The company’s efforts to advance additional vaccines is backed by its new program, mRNA Access, which will offer researchers the use of Moderna’s mRNA technology to explore new vaccines against emerging or neglected infectious disease. The program invites researchers to accelerate vaccine development to the clinic and allow the exploration of novel vaccine designs.

Moderna also aims to ensure that those low- and middle-income countries no longer experience vaccine supply as a barrier to access. The company said it is willing to license its technology for COVID-19 vaccines to manufacturers in these countries on commercially reasonable terms.

The fourth and final initiative involves a memorandum of understanding — with the assistance of the U.S. government — with the Government of the Republic of Kenya to build a state-of-the-art mRNA facility in Africa with the aim of producing up to 500 million doses of vaccines each year at the 50 µg dose level. Moderna expects to invest up to $500 million in the facility, which it expects will include drug substance manufacturing with the opportunity for fill/finish and packaging capabilities.

“Despite the rapid development timelines of our COVID-19 vaccine, and substantial efforts undertaken to scale up our manufacturing, the human toll of COVID-19 has been devastating and we must not assume that the COVID-19 pandemic will be the last pandemic that will impact global health. We are dedicated to pursuing innovative vaccine solutions to address infectious diseases that pose the greatest risk to public health through collaborative research and development,” Moderna CEO Stéphane Bancel said in the release. “We are committed to bringing the full force of our mRNA vaccine platform to combat infectious diseases of public health concern and we look forward working with global partners to be part of the solution to prevent future pandemics and help millions of people around the world.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Emergent Biosolutions
Emergent hid quality problems from FDA, House report concludes
World Changing Ideas
Fast Company 2022 World-Changing Ideas Awards highlight multiple pharma innovations
Pfizer logo
Pfizer ticks up on Street-beating Q1, lessens full-year guidance
Pfizer logo
Pfizer’s COVID-19 antiviral disappoints as post-exposure prophylactic 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards